Prenatal Diagnosis and Treatment of Spina Bifida

Guest Editor
N. Scott Adzick, Philadelphia, Pa.
Fetal growth restriction is possibly the commonest of the great obstetric syndromes. Small fetuses and newborns have a higher risk of intrauterine fetal death and poorer perinatal outcome, and suffer fetal programming and remodeling in different organ systems, which may decrease life expectancy and quality of life. This special issue deals with all of the current relevant topics and challenges concerning the management of fetal growth restriction, and contains several updated reviews about prevention, management and postnatal consequences, as well as original papers that provide new insights into the pathophysiology and clinical management of this syndrome.

Contents

- Fetal Growth Restriction as a Perinatal and Long-Term Health Problem: Clinical Challenges and Opportunities for Future (4P) Fetal Medicine: Gratacós, E.; Figueras, F.
- Update on the Diagnosis and Classification of Fetal Growth Restriction and Proposal of a Stage-Based Management Protocol: Figueras, F.; Gratacós, E.
- Evaluation of an Optimal Gestational Age Cut-Off for the Definition of Early- and Late-Onset Fetal Growth Restriction: Savchev, S.; Figueras, F.; Sanz-Cortes, M.; Cruz-Lemini, M.; Triunfo, S.; Botet, F.; Gratacos, E.
- Placental Pathology in Early-Onset and Late-Onset Fetal Growth Restriction: Mifsud, W.; Sebire, N.J.
- Survey on the Current Trends in Managing Intrauterine Growth Restriction: Savchev, S.; Figueras, F.; Gratacos, E.
- Neurodevelopment after Fetal Growth Restriction: Baschat, A.A.
- Long-Term Follow-Up of Intrauterine Growth Restriction: Cardiovascular Disorders: Demicheva, E.; Crispi, F.
- Fetal Growth Restriction at the Limits of Viability: Visser, G.H.A.; Billard, C.M.; Lees, C.
- The Disappearing Brain-Sparing Effect in Early-Onset Fetal Growth Restriction Fetuses Revisited: Yeniel, A.O.; Ergenoglu, A.M.; Sanhal, C.Y.; Akdemir, A.; Akercan, F.; Kazandi, M.; Sagol, S.

Author and Subject Index
Guidelines for Authors

Scope and Vision
The scope of *Fetal Diagnosis and Therapy* is fetal medicine in its broadest sense, including basic science and pathophysiological issues, prenatal diagnosis, clinical management and fetal therapy. The journal's main goal is to provide useful information and new insights into fetal diagnosis and therapy in the form of original research, reviews and relevant clinical cases and images. Our vision is to become a journal of reference for the multidisciplinary audience of professionals involved in clinical practice and research in fetal medicine. Authors should ensure that their work complies with all regulations laid down by their state or community and should have obtained the necessary informed consent. Neither the editors nor the publishers will accept any responsibility in the case of neglect or avoidance of these rules.

Submission
Manuscripts written in English should be submitted online along with the names, postal and e-mail addresses of at least four experts in the appropriate area of research. Selected scientist(s) will be invited to act as referee(s). Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject.

www.karger.com/fdt
Should you have any problems with your submission, please contact:
Prof. Dr. Eduard Gratacós
S. Karger AG
Editorial Office ‘Fetal Diagnosis and Therapy’
PO Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1359
Fax +41 61 306 1434
E-Mail fdt@karger.com
The manuscripts should be accompanied by a signed copyright transfer statement (please see submission website).

Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals [N Engl J Med 1997;336:309–315].

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publisher. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of *Fetal Diagnosis and Therapy* and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Categories of Manuscripts
The journal is structured into five categories.

Original Papers
Authors are invited to submit their research to the journal. Papers will be classified into four areas of interest.
- Basic Science and Pathophysiology
- Prenatal Diagnosis
- Clinical Fetal Medicine
- Fetal Therapy

Reviews and Mini-Reviews
Reviews on specific questions or topics which are felt to be of interest to the majority of readers; normally, but not exclusively, on clinical issues. They should be concise reviews or mini-reviews which give evidence and provide an answer to a well-defined aspect or question in a particular area. These reviews are normally invited but suggestions for reviews will also be considered, particularly systematic reviews accompanying a case report or case series if they are deemed to be timely and of high quality. Accepted reviews are not subject to page charges.

Novel Insights from Clinical Practice (Case Reports)
While the main aim of the journal is to publish original research and reviews, case reports which provide relevant insights into the background knowledge or which illustrate an extremely unusual clinical course are welcome. In general, case reports with a review of the literature are discouraged and this option should be reserved for exceptional cases, when the review is deemed to be of very high quality and value to the reader.

Images in Fetal Medicine
The section aims to publish images of high interest, either because they illustrate or aid understanding of an important concept or because the image is of particular quality. Images of all kinds are foreseen, including ultrasound, MRI and fetoscopy. Combinations of prenatal imaging with fetoscopic, postnatal, surgical or pathological imaging are particularly encouraged. Authors may be invited to transfer some clinical cases to this section if the images are particularly good. Papers published in this section will be considered as case reports for Medline purposes.

Letters to the Editor
Letters are encouraged if they directly concern articles previously published in this journal or clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. Letters on general scientific or medical subjects in fetal medicine are also welcome.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be rejected and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Arrangement
Title page: The first page of each paper should indicate the title, the authors’ names, and the institute where the work was conducted. A short title for use as a running head, as well as the full address of the author to whom correspondence should be sent, are also required.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Please refer to the ‘Instructions for Preparation of Specific Manuscript Categories’.

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and Illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. For technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 x 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see http://www.karger.com/ftd).

Instructions for Preparation of Specific Manuscript Categories

Original Papers
The guidelines below should be followed as closely as possible. This will help the editors and reviewers to interpret the aims and value of your research.

An abstract of up to 200 words, structured with the same headings as below, should be provided.

Introduction
This should clearly state the research question and introduce the condition and the clinical or research problem being addressed. Lengthy descriptions of previous evidence, particularly information that may be important for the topic in general but is not strictly related to the research question, should be avoided. At the end of the introduction please clarify what new or complementary information your research is providing with respect to existing knowledge or previous research.

Material and Methods
The section must contain clear information on permissions obtained by ethical committees, inclusion and exclusion criteria, methods of research, variables evaluated and main outcome measures, along with other secondary variables evaluated, definitions used, and statistical analyses.

Results
The findings of the study should be described concisely following the same structure as in Materials and Methods. The text should complement, but not duplicate, the information contained in the tables and figures. Comments on the findings in this section should be avoided.

Discussion
The Discussion should be as structured as possible, and contain at least the following paragraphs, each with information responding to the following questions:
- What are the main findings?
- How do they compare with previous studies: which similarities and differences and the reasons for them?
- What are the pathophysiological basis and insights reinforced or newly provided by the findings? (If applicable.)
Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

<table>
<thead>
<tr>
<th></th>
<th>Print or Online</th>
<th>Print+Online combined</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal subscription</td>
<td>CHF 1160.00</td>
<td>CHF 1256.00</td>
</tr>
<tr>
<td>EUR 967.00</td>
<td>EUR 1045.00</td>
<td></td>
</tr>
<tr>
<td>USD 1184.00</td>
<td>USD 1280.00</td>
<td></td>
</tr>
</tbody>
</table>

Discount subscription prices:
- International Fetal Medicine and Surgery Society (www.ifmss.org)
- and the ‘Fetus as a Patient’ Society

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc.

222 Rosewood Drive
Danvers, MA 01923 (USA)

A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box CH–4009 Basel (Switzerland).

General Information

Subscription Orders:
Orders can be placed at agencies, bookstores, directly with the Publisher or, in the case of photocopying, direct payment of a specified fee must be obtained from the copyright owner, S. Karger AG, P.O. Box CH–4009 Basel (Switzerland).

S. Karger AG
Medical and Scientific Publishers
Allschwilerstrasse 10
CH–4009 Basel
Switzerland

t: +41 61 306 11 11
f: +41 61 306 12 34
e: karger@karger.com
w: www.karger.com

(for courier services only: Allschwilerstrasse 10
CH–4055 Basel)

Change of Address:
Both old and new address should be sent to the subscription source.

or further Karger offices
or representatives:

Germany
S. Karger GmbH
Postfach 79095 Freiburg
Deutschland
(Hausadresse: Wilhelmsstrasse 20A, 79098 Freiburg)
t: +49 761 45 20 70
f: +49 761 45 20 714
e: information@karger.de
w: www.karger.de

Japan
Karger Japan, Inc.
Shiba Daimon Asahi Bldg. 2F
1-2-23 Shiba Daimon
Minato-ku
Tokyo 105-0012
Japan
t: +81 3 6435 6242
f: +81 3 6435 6244
e: publisher@karger.jp
w: www.karger.jp

USA
S. Karger Publishers, Inc.
26 West Avon Road
PO. Box 529
Unionville, CT 06085
USA
tell: +1 800 828 5479
c: +1 860 675 7834
e: karger@snet.net

Print or Online subscription:
CHF 2990.00
EUR 2417.00
USD 2895.00
USD 3403.00

EUR 64.00
USD 98.00

Postage and handling (added to print and print+online)
CHF 76.00
EUR 112.00

Discount subscription prices:
- International Fetal Medicine and Surgery Society (www.ifmss.org)
- and the ‘Fetus as a Patient’ Society

France
Enter & Read
Albertine Lugnibuhl
23, rue du Départ, boîte 37
75014 Paris
France
t: +33 (0) 6 81 94 76 85
e: albertineluginbuhl@orange.fr

South East Asia, China and Taiwan
Karger Regional Office (Malaysia)
Level 28-03 03A, PJ Exchange
No. 16A, Persiaran Barat
46050 Petaling Jaya
Selangor Darul Ehsan
Malaysia
t: +60 3 7962 0158
e: service@karger.cn; r.chew@karger.cn
Contents

See the journal website for contents
22\textsuperscript{nd} World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI)

Budapest, Hungary
September 17-20, 2015

COGI is your avenue
to showcase your abstract and exchange ideas.
Abstract Submission Deadline: June 14, 2015

More opportunities to learn:
- Scientific discussions on current clinical controversies covering advances in more than 15 sub-disciplines
- Presentations by more than 100 interdisciplinary opinion leaders
- Robert G. Edwards, Nobel Prize Laureate exclusive lecture

More opportunities to connect:
- Reunite with your colleagues and explore new partnerships

More opportunities to share:
- Hundreds of gynecologists and scientists from all over the world will introduce their work in oral and poster presentations
- Special young scientists competition for best abstract presenters

www.congressmed.com/cogi
34th Annual Meeting of the
International Fetal Medicine and Surgery Society
June 19-23, 2015
Hersonissos, Crete, Greece

Registration and hotel reservation available through the web site.

Critical dates:

- April 15, 2015: Deadline for abstracts for Travel & Young Investigator Awards
- April 18, 2015: End of early-bird registration
- May 15, 2015: Deadline for regular abstract submission

For more information, please go to http://www.ifmss.org

or contact jan.deprest@uzleuven.be or leen.mortier@uzleuven.be

Fetal Diagnosis and Therapy is the official journal of the International Fetal Medicine and Surgery Society (IFMSS). www.ifmss.org
An extensive update providing practical help

Neonatal Pharmacology and Nutrition Update

Editors
Francis B. Mimouni
Johannes N. van den Anker

In order to provide safe and effective drug therapy to neonates, it is necessary to know about and understand the impact their development has on the pharmacokinetics and pharmacodynamics of drugs. The fact that children are different and neonates very different from adults means that, in neonates, it would be unwise to dose medications by scaling down adult doses proportionally, simply attempting to match their smaller weight and/or body surface area. When one makes decisions about neonatal drug therapy, one must not only take into consideration the available data but also critically assess and interpret this information within the context of fetal development and maturational processes as well as within the context of diseases that might affect a drug’s biodisposition. This book includes the latest information on the regulation and scientific basis of drug development and also provides a rationale for formula development for preterm infants. It offers guidance on how to translate pharmacokinetic data into dosing recommendations and also covers legal and regulatory issues relating to neonatal pharmacotherapy.

Contents

• Foreword: Kiess, W.
• Preface: Mimouni, F.B.; van den Anker, J.N.
• Influence of Maturation and Growth on Drug Metabolism from Fetal to Neonatal to Adult Life: Lindemalm, S.; van den Anker, J.N.
• How to Translate Pharmacokinetic Data into Dosing Recommendations: Krekels, E.H.J.; Knibbe, C.A.J.; Pokorna, P.; Tibboel, D.
• Pharmacovigilance in Neonatal Intensive Care: Turner, M.A.; Hill, H.
• Neonatal Formulations and Additives: Allegaert, K.; Turner, M.A.; van den Anker, J.N.
• Modelling and Simulation to Support Neonatal Clinical Trials: Khalil, F.; Läer, S.
• A Systematic Review of Paracetamol and Closure of Patent Ductus Arteriosus: Ready for Prime Time?: Hammerman, C.; Mimouni, F.B.; Bin-Nun, A.
• Formulation of Preterm Formula: What’s in it, and Why?: Mimouni, F.B.; Mandel, D.; Lubetzky, R.
• Neonatal Pharmacotherapy: Legal and Regulatory Issues: Bax, R.; Tomasi, P.

Author Index / Subject Index

Dear Librarian

I have reviewed this publication and would like to recommend it for our library.

Recommended by:

______________________________

Department:

______________________________

Date:

______________________________

Signature:

______________________________

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.
Update in the analysis of cell-free DNA testing

New Advances in Cell-Free DNA Analysis of Maternal Blood

Editor
Kypros Nicolaides

Prenatal screening by cell-free (cf) DNA in maternal plasma has opened a new landscape for fetal medicine. Large clinical series have demonstrated that cfDNA analysis of maternal blood can achieve trisomy 21 detection rate of 99% for false-positive rate below 0.1%, which is a great improvement upon the current screening strategies. However, there is a need to define the optimal way of combining cfDNA testing with other first trimester exams. Likewise, several commercial cfDNA tests have rapidly become available, but their main features are not always readily comprehensible for clinicians. In this special issue, we combine a practical overview from a clinical perspective with meta-analysis and theoretical models that help explain the impact of introducing cfDNA testing, along with a number of important recent research contributions. This issue offers clinicians involved in fetal medicine up-to-date and useful information about the current state of cfDNA testing and how to use it in their daily practice.

Contents
• Clinical Perspective of Cell-Free DNA Testing for Fetal Aneuploidies: Gratacós, E.; Nicolaides, K.
• Patient’s Choice between a Non-Invasive Prenatal Test and Invasive Prenatal Diagnosis Based on Test Accuracy: Chan, Y.M.; Leung, T.Y.; Chan, O.K.C.; Cheng, Y.K.Y.; Sahota, D.S.
• Cell-Free DNA Analysis for Trisomy Risk Assessment in First-Trimester Twin Pregnancies: Gil, M.M.; Quezada, M.S.; Bregant, B.; Syngelaki, A.; Nicolaides, K.H.
• Prenatal Detection of Fetal Triploidy from Cell-Free DNA Testing in Maternal Blood: Nicolaides, K.H.; Syngelaki, A.; Gil, M.M.; Quezada, M.S.; Zinevich, Y.

Author Index / Subject Index

The easiest way to order: www.karger.com/fdt

Karger – Medical and Scientific Publishers
CH–4009 Basel, Switzerland
orders@karger.com, t +41 61 306 12 34
www.karger.com
A fresh look at basic and clinical aspects of DSD

Understanding Differences and Disorders of Sex Development (DSD)

Editors
Olaf Hiort
S. Faisal Ahmed

Ten years ago a group of experts assembled in Chicago to develop a consensus on the management of conditions previously described as intersex. The consequences of this consensus have been far reaching, including a change in nomenclature, the development of greater collaboration across geographical boundaries, and a move towards greater involvement of patients and parents. Moreover, an international registry was established, as well as research and clinical networks.

This book brings together a thorough overview on all these topics. Furthermore, the major technological advances in diagnostic, genetic, and biochemical capabilities over the past 10 years are outlined in detail. Offering a comprehensive update on various aspects of disorders of sex development (DSD), this book will be essential reading to all clinicians who are involved in delivering health care to patients with a DSD, as well as scientists involved in biomedical research related to DSD.

Contents

Foreword: Hiort, O.; Ahmed, S.F.
Preface: Hughes, I.; Lee, P.

Concepts
- Gonadal Development: Lucas-Herald, A.K.; Bashamboo, A.
- The masculinization Programming Window: Welsh, M.; Suzuki, H.; Yamada, G.
- Androgen Action: Werner, R.; Holterhus, P.-M.

Technological Advances
- Steroid Biochemistry: Kannath, C.; Wudy, S.A.; Krone, N.
- Next Generation Sequencing for Disorders of Sex Development: Tobias, E.S.; McElreavey, K.
- Advances in Neuroimaging: Rodie, M.E.; Forbes, K.P.; Muir, K.
- Imaging, Endoscopy and Diagnostic Surgery: Wünsch, L.; Buchholz, M.
- Fertility Issues in the Management of Patients with Disorders of Sex Development: Guercio, G.; Rey, R.A.

Communication
- Improving the Communication of Healthcare Professionals with Affected Children and Adolescents: Nordenström, A.; Thyen, U.
- Working with Adolescents and Young Adults to Support Transition: Gleeson, H.; Wisniewski, A.B.

Past Experiences of Adults with Disorders of Sex Development: GrAPsIA; Audi, L.
The Use of Drugs
- Sex Hormone Replacement in Disorders of Sex Development: Birnbaum, W.; Bertelloni, S.
- Hydrocortisone Replacement in Disorders of Sex Development: Blankenstein, O.

Tumours
- Advances in Molecular Markers of Germ Cell Cancer in Patients with Disorders of Sex Development: van der Zwan, Y.G.; Cools, M.; Looijenga, L.H.J.

Timing of Surgery
- Timing of Hypospadias Repair in Patients with Disorders of Sex Development: Springer, A.; Baskin, L.S.
- Timing of Surgery for Feminizing Genitoplasty in Patients Suffering from Congenital Adrenal Hyperplasia: Eckoldt-Wolke, F.
- Timing of Feminising Surgery in Disorders of Sex Development: Wolffentubbel, K.P.; Crouch, N.S.
- Phalloplasty: A Panacea for 46,XY Disorder of Sex Development Conditions with Penile Deficiency?: Callens, N.; Hoebeke, P.

International Aspects
- Rare Diseases Research and Practice: Polizzi, A.; Balsamo, A.; BaI, M.O.; Tarucio, D.
- Achieving Diagnostic Certainty in Resource-Limited Settings: Raza, J.; Mazen, I.
- International Networks for Supporting Research and Clinical Care in the Field of Disorders of Sex Development: Ahmed, S.F.; Bryce, J.; Hiort, O.

Author Index
Subject Index

www.karger.com/endev
Cells Tissues Organs aims at bridging the gap between cell biology and developmental biology and the emerging fields of regenerative medicine (stem cell biology, tissue engineering, artificial organs, in vitro systems and transplantation biology). CTO offers a rapid and fair peer-review and exquisite reproduction quality. Special topic issues, entire issues of the journal devoted to a single research topic within the range of interests of the journal, are published at irregular intervals.

Cells Tissues Organ
Founded: 1945
Category: Basic Research
Field of Interest: Cell Biology

Listed in bibliographic services, including Current Contents®/Life Sciences, Pubmed/MEDLINE, Biological Abstracts, EMBASE/Excerpta Medica

2015: Volumes 201, 202
6 issues per volume
Language: English
ISSN 1422–6405
e-ISSN 1422–6421

Impact Factor: 2.138

Selected contributions
- Influence of Hystoplasmosis in the Intervertebral Disc on the Biological Behaviors of Rat Adipose- and Nucleus Pulposus-Derived Mesenchymal Stem Cells: Li, H.; Tao, Y.; Li, F.; Chen, G.; Chen, Q. (Hangzhou)
- Aorta-Derived Mesangioblasts Can Be Differentiated into Functional Uterine Epithelium, but Not Prostatic Epithelium or Epidermis, by Instructive Mesenchymes: Simon, L. (New Orleans, La.), Cooke, P.S. (Gainesville, Fla.), Berry, S.E. (Urbana, Ill.)
- Localization, Not Important in All Tumor-Suppressing Properties: A Lesson Learnt from Scribble: Elsum, J.A. (Melbourne, Vic.), Humbert, P.O. (Melbourne, Vic./Parkville, Vic.)
- Embryonic Stem Cells Facilitate the Isolation of Persistent Clonal Cardiovascular Progenitor Cell Lines and Leukemia Inhibitor Factor Maintains Their Self-Renewal and Myocardial Differentiation Potential in vitro: Hoebauer, J.; Heher, P.; Gottschamel, T.; Scheinast, M.; Auner, H.; Walder, D.; Wiedner, M.; Taubenschmid, J.; Miksch, M.; Sauer, T.; Schultheis, M. (Vienna); Kuzmenkin, A. (Cologne); Seiser, C. (Vienna); Hescheler, J. (Cologne); Weitzer, G. (Vienna)

More information at www.karger.com/cto
Prenatal Diagnosis and Treatment of Spina Bifida

In this issue the authors from The Children’s Hospital of Philadelphia along with international colleagues share findings and present best practices gleaned from – and subsequent to – the MOMS (Management of Myelomeningocele Study) trial. They provide a detailed account of the specific roles the different diagnostic and imaging modalities (maternal serum α-fetoprotein, ultrasound, magnetic resonance imaging, and echocardiography) played in diagnosis, treatment, and monitoring. Nuances of the fetal myelomeningocele (MMC) repair technique and long-term urologic functional outcomes as well as the progress towards fetal MMC repair using tissue engineering techniques are evaluated and analyzed in this publication. Find out about the fetal MMC repair outcomes at The Children’s Hospital of Philadelphia since the MOMS trial concluded!

This issue is directed at obstetricians, maternal-fetal medicine specialists, pediatric surgeons, neurosurgeons, neonatologists, radiologists, anesthesiologists, cardiologists, geneticists, pediatricians, nurses, and social workers who play a crucial role within the multidisciplinary teams that manage fetuses with anatomic or genetic defects.